Is there new hope for therapeutic matrix metalloproteinase inhibition?

Key Points Despite promising preclinical data supporting the blockage of MMPs as a treatment for cancer, all Phase III cancer trials failed. This might be due to inadequate clinical trial design, the characteristics of the MMP inhibitors used, poor knowledge on the complexity of the MMPs and discrep...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature reviews. Drug discovery 2014-12, Vol.13 (12), p.904-927
Hauptverfasser:	Vandenbroucke, Roosmarijn E., Libert, Claude
Format:	Artikel
Sprache:	eng
Schlagworte:	631/154 631/250/256/1980 631/45/49/1141 692/699/255 Analysis Animals Antimitotic agents Antineoplastic agents Biomedicine Biotechnology Cancer Research Clinical trials Complications and side effects Dosage and administration Humans Inflammation - drug therapy Inflammation - enzymology Inflammation Mediators - antagonists & inhibitors Inflammation Mediators - metabolism Inflammatory diseases Matrix Metalloproteinase Inhibitors - chemistry Matrix Metalloproteinase Inhibitors - pharmacology Matrix Metalloproteinase Inhibitors - therapeutic use Matrix Metalloproteinases - metabolism Medicinal Chemistry Molecular Medicine Neoplasms - drug therapy Neoplasms - enzymology Pharmacology/Toxicology review-article Sepsis Signal Transduction - drug effects Signal Transduction - physiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!